Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Department of Rheumatology & Immunology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Future Oncol. 2022 Mar;18(7):883-896. doi: 10.2217/fon-2021-1217. Epub 2021 Nov 26.
To compare the survival of advanced lung cancer patients treated with immune checkpoint inhibitors in different PD-L1 expression. We performed a network meta-analysis based on 25 trials involving 12,224 patients with different PD-L1 expression levels. The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1-49% PD-L1 expression. As for patients with ≥50% PD-L1 expression, platinum-based chemotherapy plus pembrolizumab/atezolizumab and pembrolizumab/cemiplimab monotherapy were associated with better survival than chemotherapy. These results provide reference for selecting the optimum immunotherapy method based on the expression of PD-L1 in patients with advanced lung cancer.
比较不同 PD-L1 表达水平的晚期肺癌患者接受免疫检查点抑制剂治疗的生存情况。我们基于涉及不同 PD-L1 表达水平的 12224 例患者的 25 项试验进行了网络荟萃分析。结果表明，对于 PD-L1 表达<1%的患者，铂类化疗联合培美曲塞或纳武单抗和伊匹单抗与最佳生存率相关，而只有铂类化疗联合培美曲塞与化疗相比，在 PD-L1 表达 1-49%的患者中产生了更好的生存。对于 PD-L1 表达≥50%的患者，铂类化疗联合培美曲塞/阿特珠单抗和培美曲塞/西米普利单抗单药治疗与化疗相比与更好的生存相关。这些结果为基于晚期肺癌患者 PD-L1 表达选择最佳免疫治疗方法提供了参考。
